|
US20050060764A1
(en)
*
|
2003-09-17 |
2005-03-17 |
Susan Gregory |
Mouse model for bone metabolism
|
|
US6919434B1
(en)
|
1995-02-20 |
2005-07-19 |
Sankyo Co., Ltd. |
Monoclonal antibodies that bind OCIF
|
|
IL117175A
(en)
*
|
1995-02-20 |
2005-11-20 |
Sankyo Co |
Osteoclastogenesis inhibitory factor protein
|
|
US7632922B1
(en)
*
|
1995-12-22 |
2009-12-15 |
Amgen, Inc. |
Osteoprotegerin
|
|
US20050147611A1
(en)
*
|
1995-12-22 |
2005-07-07 |
Amgen Inc. |
Combination therapy for conditions leading to bone loss
|
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
|
US6479254B2
(en)
|
1996-03-22 |
2002-11-12 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II
|
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
|
US6495520B2
(en)
|
1996-03-22 |
2002-12-17 |
Human Genome Sciences, Inc. |
Apoptosis Inducing Molecule II and methods of use
|
|
WO1998025958A2
(en)
*
|
1996-12-13 |
1998-06-18 |
Schering Corporation |
Mammalian cell surface antigens comprising structural motifs characteristic of a member of the tnf ligand family
|
|
EP2003203A1
(en)
|
1996-12-23 |
2008-12-17 |
Immunex Corporation |
Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
|
|
IL130491A
(en)
*
|
1996-12-23 |
2011-10-31 |
Immunex Corp |
Dna encoding rank polypeptide, the rank polypeptide and use thereof
|
|
AU2008200700C1
(en)
*
|
1997-04-15 |
2013-04-04 |
Daiichi Sankyo Co., Ltd |
Novel Protein and Process for Producing The Same
|
|
EP2336168A1
(en)
*
|
1997-04-15 |
2011-06-22 |
Sankyo Company Limited |
Novel protein and method for producing the protein
|
|
US6316408B1
(en)
*
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
|
ATE363533T1
(de)
*
|
1997-04-16 |
2007-06-15 |
Amgen Inc |
Osteoprotegerin bindende proteine und rezeptoren
|
|
CA2229449A1
(en)
*
|
1997-04-25 |
1998-10-25 |
Takeda Chemical Industries, Ltd. |
Novel receptor protein and its use
|
|
WO1998054201A1
(en)
*
|
1997-05-29 |
1998-12-03 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like protein 8
|
|
CN1183159C
(zh)
|
1997-09-24 |
2005-01-05 |
三共株式会社 |
破骨细胞形成抑制因子单克隆抗体、其用途和试剂盒
|
|
US7063960B2
(en)
|
1997-12-12 |
2006-06-20 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
|
WO1999029865A2
(en)
*
|
1997-12-12 |
1999-06-17 |
The Rockefeller University |
A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
|
|
US7019119B2
(en)
|
1997-12-12 |
2006-03-28 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
|
ATE412746T1
(de)
|
1998-05-14 |
2008-11-15 |
Immunex Corp |
Verfahren zur hemmung der wirkung der osteoklasten
|
|
US20020106728A1
(en)
*
|
2000-06-20 |
2002-08-08 |
Genentech, Inc. |
NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
|
|
SI1114166T1
(en)
*
|
1998-09-15 |
2005-10-31 |
Pharmexa A/S |
Method for down-regulating osteoprotegerin ligand activity
|
|
CN1318105A
(zh)
|
1998-09-15 |
2001-10-17 |
M&E生物技术公司 |
负调节Osteoprotegerin配体活性的方法
|
|
IL145676A0
(en)
|
1999-04-12 |
2002-06-30 |
Genentech Inc |
Tumor necrosis factor homologs and nucleic acids encoding the same
|
|
US6492124B1
(en)
|
1999-06-11 |
2002-12-10 |
The Rockefeller University |
Trance activated signal transduction pathways in osteoclasts
|
|
US6872806B1
(en)
*
|
1999-06-25 |
2005-03-29 |
The Governors Of The University Of Alberta |
Polypeptide compositions formed using a coiled-coil template and methods of use
|
|
ES2392392T3
(es)
|
1999-06-28 |
2012-12-10 |
Genentech, Inc. |
Métodos para producir ligando Apo-2 utilizando iones metálicos divalentes
|
|
US6673771B1
(en)
|
1999-07-28 |
2004-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of inhibiting osteoclast activity
|
|
ATE448781T1
(de)
*
|
1999-07-28 |
2009-12-15 |
Univ Pennsylvania |
Methoden zur hemmung der aktivität der osteoklasten
|
|
AUPQ314799A0
(en)
*
|
1999-09-29 |
1999-10-21 |
University Of Western Australia, The |
Bone cell factor
|
|
US6171860B1
(en)
|
1999-11-05 |
2001-01-09 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of rank expression
|
|
WO2001036637A1
(en)
*
|
1999-11-17 |
2001-05-25 |
Immunex Corporation |
Receptor activator of nf-kappa b
|
|
GB9930616D0
(en)
|
1999-12-24 |
2000-02-16 |
Mathilda & Terence Kennedy Ins |
Activation and inhibition of the immune system
|
|
JP5062606B2
(ja)
|
2000-02-16 |
2012-10-31 |
ジェネンテック， インコーポレイテッド |
Ｔｎｆ関連分子の活性を調節するためのアゴニスト及びアンタゴニストの使用
|
|
US20030103978A1
(en)
*
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
|
DE60134459D1
(de)
†
|
2000-02-23 |
2008-07-31 |
Amgen Inc |
Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
|
|
ES2637801T3
(es)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
|
WO2001091793A1
(en)
*
|
2000-05-26 |
2001-12-06 |
Smithkline Beecham Corporation |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
WO2002009755A2
(en)
|
2000-07-27 |
2002-02-07 |
Genentech, Inc. |
Apo-2l receptor agonist and cpt-11 synergism
|
|
US20040247596A1
(en)
*
|
2000-08-18 |
2004-12-09 |
Odgren Paul R. |
TRANCE regulation of chondrocyte differentiation
|
|
AU2001288342A1
(en)
*
|
2000-08-21 |
2002-03-04 |
Smith Kline Beecham Corporation |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
WO2002024896A2
(en)
*
|
2000-09-22 |
2002-03-28 |
Immunex Corporation |
Screening assays for agonists or antagonists of receptor activat or of nf-kb
|
|
US7128911B2
(en)
*
|
2001-01-19 |
2006-10-31 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of bone disease
|
|
US20040132971A1
(en)
*
|
2001-02-09 |
2004-07-08 |
Haaning Jesper Mortensen |
Rank ligand-binding polypeptides
|
|
WO2002064782A2
(en)
*
|
2001-02-09 |
2002-08-22 |
Maxygen Holdings Ltd. |
Rank ligand-binding polypeptides
|
|
US20030013651A1
(en)
*
|
2001-03-22 |
2003-01-16 |
Barnes-Jewish Hospital |
Stimulation of osteogenesis using rank ligand fusion proteins
|
|
EA200301041A1
(ru)
*
|
2001-03-22 |
2004-08-26 |
Барнс-Джуиш Хоспитал |
Стимуляция остеогенеза с использованием гибридных белков лиганда для rank
|
|
CN1509328A
(zh)
*
|
2001-03-23 |
2004-06-30 |
|
Opg配体调节免疫应答的作用
|
|
WO2002092623A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Research Development Foundation |
INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
|
|
US20040167072A1
(en)
*
|
2001-05-11 |
2004-08-26 |
Aggarwal Bharat B. |
Inhibitors of receptor activator of NF-kappaB and uses thereof
|
|
EP1399175A4
(en)
*
|
2001-05-17 |
2005-11-30 |
Immunex Corp |
THERAPEUTIC USE OF RANK ANTAGONISTS
|
|
US20040213788A1
(en)
*
|
2001-05-18 |
2004-10-28 |
Sweet Raymond W. |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
MXPA03011270A
(es)
*
|
2001-06-06 |
2004-03-18 |
Immunex Corp |
Uso de antagonistas rank para tratar cancer.
|
|
EP1414517A4
(en)
*
|
2001-06-26 |
2008-02-06 |
Photomed Technologies Inc |
MULTIPLE WAVELENGTH ILLUMINATOR
|
|
MY143582A
(en)
|
2001-06-26 |
2011-05-31 |
Amgent Fremont Inc |
Antibodies to opgl
|
|
CA2451680C
(en)
|
2001-07-03 |
2011-04-19 |
Genentech, Inc. |
Human dr4 antibodies and uses thereof
|
|
US20030050223A1
(en)
*
|
2001-08-09 |
2003-03-13 |
Jonathan Lam |
Crystal forms and mutants of RANK ligand
|
|
CA2461292A1
(en)
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
|
EP1442297A4
(en)
*
|
2001-10-12 |
2004-12-15 |
Barnes Jewish Hospital |
METHOD FOR SCREENING OSTEOGENIC COMPOUNDS
|
|
US20030100068A1
(en)
*
|
2001-10-12 |
2003-05-29 |
Jonathan Lam |
RANKL mimics and uses thereof
|
|
US20030109444A1
(en)
*
|
2001-10-12 |
2003-06-12 |
Jonathan Lam |
Bone anti-resorptive compounds
|
|
EP1444341A2
(en)
*
|
2001-10-15 |
2004-08-11 |
Barnes-Jewish Hospital |
Rankl mimics and uses thereof
|
|
DE60237841D1
(de)
|
2001-11-13 |
2010-11-11 |
Genentech Inc |
Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
|
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
|
US20030166559A1
(en)
*
|
2002-01-04 |
2003-09-04 |
Desjarlais John R. |
Dominant negative proteins and methods thereof
|
|
US20040170602A1
(en)
*
|
2002-01-04 |
2004-09-02 |
Desjarlais John R. |
Dominant negative proteins and methods thereof
|
|
WO2003059281A2
(en)
*
|
2002-01-04 |
2003-07-24 |
Xencor |
Novel variants of rankl protein
|
|
US7381792B2
(en)
*
|
2002-01-04 |
2008-06-03 |
Xencor, Inc. |
Variants of RANKL protein
|
|
WO2003080671A1
(en)
*
|
2002-03-21 |
2003-10-02 |
Komed Co., Ltd. |
Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
|
|
PL375041A1
(en)
*
|
2002-04-05 |
2005-11-14 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
|
JP4574350B2
(ja)
|
2002-06-24 |
2010-11-04 |
ジェネンテック， インコーポレイテッド |
Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
|
|
US20040138162A1
(en)
*
|
2002-08-30 |
2004-07-15 |
Roodman G. David |
Method of resisting osteoclast formation
|
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
MXPA05006147A
(es)
*
|
2002-12-10 |
2005-08-26 |
Schering Plough Ltd |
Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
|
|
DE602004026157D1
(de)
*
|
2003-01-10 |
2010-05-06 |
Protein Crystal Co Ltd |
Proteinkomplex, verfahren zu dessen herstellung und verwendung davon
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
WO2005028633A2
(en)
*
|
2003-09-17 |
2005-03-31 |
Isis Pharmaceuticals, Inc. |
Modulation of rankl expression
|
|
US7252833B2
(en)
*
|
2003-11-18 |
2007-08-07 |
Skeletal Kinetics, Llc |
Calcium phosphate cements comprising an osteoclastogenic agent
|
|
US7704686B2
(en)
*
|
2003-12-29 |
2010-04-27 |
Toudai Tlo, Ltd. |
Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
|
|
SG151294A1
(en)
|
2004-03-23 |
2009-04-30 |
Biogen Idec Inc |
Receptor coupling agents and therapeutic uses thereof
|
|
EP2412816B1
(en)
|
2004-07-26 |
2014-12-03 |
Pfenex Inc. |
Process for improved protein expression by strain engineering
|
|
MX2007001221A
(es)
|
2004-08-04 |
2007-03-23 |
Amgen Inc |
Anticuerpos para proteina dickkopf-1 (dkk-1).
|
|
CA2575152A1
(en)
|
2004-08-06 |
2006-02-16 |
Genentech, Inc. |
Method for predicting sensitivity of mammalian cells to apo2l/trail comprising deletion of biomarker expression
|
|
RU2410438C2
(ru)
|
2004-08-06 |
2011-01-27 |
Дженентек, Инк. |
Анализы и способы, использующие биомаркеры
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
RU2007119989A
(ru)
*
|
2004-12-02 |
2009-01-10 |
Домантис Лимитед (Gb) |
Композиции, слитые конструкции и конъюгаты plad домена
|
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
RU2409817C2
(ru)
|
2005-08-16 |
2011-01-20 |
Дженентек, Инк. |
Анализы и способы применения биомаркеров
|
|
AU2006318539B2
(en)
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
|
WO2007095161A2
(en)
*
|
2006-02-14 |
2007-08-23 |
New York University |
Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
|
|
EP1854458A1
(en)
*
|
2006-05-08 |
2007-11-14 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Use of a compound with RANKL activity
|
|
JP5210156B2
(ja)
|
2006-05-12 |
2013-06-12 |
学校法人慶應義塾 |
炎症性疾患の検出並びに炎症性疾患の予防又は治療用組成物
|
|
WO2008044379A1
(fr)
|
2006-10-11 |
2008-04-17 |
Oriental Yeast Co., Ltd. |
Modèle animal de perte osseuse
|
|
WO2008044797A1
(fr)
|
2006-10-11 |
2008-04-17 |
Oriental Yeast Co., Ltd. |
Animal modèle d'ostéopénie
|
|
CA2666415C
(en)
|
2006-10-11 |
2012-11-27 |
Oriental Yeast Co., Ltd. |
Agent containing fused protein of soluble rankl with epitope tag
|
|
EP2615172A1
(en)
|
2007-04-27 |
2013-07-17 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
JP5191487B2
(ja)
|
2007-06-05 |
2013-05-08 |
オリエンタル酵母工業株式会社 |
新しい骨量増加薬
|
|
CN101932935A
(zh)
*
|
2007-06-20 |
2010-12-29 |
先灵公司 |
用于炎性关节病抗白介素-17a治疗的关节破坏生物标记
|
|
MX2010001918A
(es)
|
2007-08-21 |
2010-03-11 |
Amgen Inc |
Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino.
|
|
KR100911852B1
(ko)
|
2007-11-26 |
2009-08-11 |
고려대학교 산학협력단 |
유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
|
|
WO2009105934A1
(zh)
*
|
2008-02-27 |
2009-09-03 |
上海先导药业有限公司 |
抗人rankl单克隆抗体
|
|
AR073072A1
(es)
|
2008-08-19 |
2010-10-13 |
Regeneron Pharma |
Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
|
|
US8657662B2
(en)
|
2008-09-04 |
2014-02-25 |
Patent Investment & Licensing Company |
Gaming device having variable speed of play
|
|
US9435811B2
(en)
|
2008-09-30 |
2016-09-06 |
Oriental Yeast Co., Ltd |
Inducer of chondrocyte proliferation and differentiation
|
|
CN101712964B
(zh)
*
|
2008-10-08 |
2013-05-08 |
上海科新生物技术股份有限公司 |
抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物
|
|
MX2011005481A
(es)
|
2008-11-25 |
2011-08-17 |
Biogen Idec Inc |
Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
|
|
CN101514232B
(zh)
*
|
2009-03-25 |
2013-06-19 |
上海科新生物技术股份有限公司 |
一种RANKL-Fc融合蛋白及其制备方法和用途
|
|
US9079957B2
(en)
|
2009-04-16 |
2015-07-14 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
|
|
KR101153393B1
(ko)
*
|
2009-09-21 |
2012-06-07 |
고려대학교 산학협력단 |
점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
|
|
EP3372617B1
(en)
|
2010-04-02 |
2024-07-24 |
Amunix Pharmaceuticals, Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
ES2739503T3
(es)
|
2010-07-09 |
2020-01-31 |
Bioverativ Therapeutics Inc |
Moléculas de cadena simple procesables y polipéptidos producidos usándolas
|
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
|
EP2434285A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer diagnostics
|
|
DK3091085T3
(da)
|
2010-10-06 |
2019-05-06 |
Inst Catalana Recerca Estudis Avancats |
Fremgangsmåde til at designe en terapi mod brystcancermetastase
|
|
EP2692359B1
(en)
|
2011-03-31 |
2017-06-07 |
Oriental Yeast Co., Ltd. |
Cancer immunopotienting agent containing rankl antagonist
|
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
|
FR2980711A1
(fr)
*
|
2011-10-03 |
2013-04-05 |
Centre Nat Rech Scient |
Modulation du systeme immunitaire et des cellules stromales via rank
|
|
EP2776066B1
(en)
|
2011-11-07 |
2018-09-19 |
Universite Laval |
Rank/rankl antagonists for use in treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies
|
|
EP2650682A1
(en)
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Method for the prognosis and treatment of cancer metastasis
|
|
EP3467124A1
(en)
|
2012-06-06 |
2019-04-10 |
Fundació Institut de Recerca Biomèdica IRB (Barcelona) |
Method for the diagnosis, prognosis and treatment of lung cancer metastasis
|
|
US10119171B2
(en)
|
2012-10-12 |
2018-11-06 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
|
JP6074049B2
(ja)
|
2012-10-12 |
2017-02-01 |
インバイオモーション エセ．エレ． |
ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
EA037906B1
(ru)
|
2013-03-15 |
2021-06-04 |
Биовератив Терапьютикс Инк. |
Препараты полипептида фактора ix
|
|
AU2014229505B2
(en)
|
2013-03-15 |
2020-02-27 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the prognosis and treatment of cancer metastasis
|
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
|
US20160032399A1
(en)
|
2013-03-15 |
2016-02-04 |
Inbiomotion S.L. |
Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
|
|
CA2920376A1
(en)
|
2013-08-07 |
2015-02-12 |
Martin Blomberg JENSEN |
Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
|
|
WO2015030701A1
(en)
*
|
2013-08-24 |
2015-03-05 |
R-Pharm Overseas, Inc. |
Fully human antibodies against human rankl
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
WO2015035215A1
(en)
|
2013-09-05 |
2015-03-12 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
JP6550045B2
(ja)
|
2013-10-09 |
2019-07-24 |
フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） |
乳がんに由来する骨の転移がんの予後診断および処置のための方法
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
EP4035664A3
(en)
|
2014-03-28 |
2022-11-30 |
Duke University |
Treating cancer using selective estrogen receptor modulators
|
|
US10156562B2
(en)
|
2014-05-16 |
2018-12-18 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
|
KR20170093182A
(ko)
|
2014-12-11 |
2017-08-14 |
인바이오모션 에스.엘. |
인간 c-maf에 대한 결합 구성원
|
|
CN104829725A
(zh)
*
|
2015-01-21 |
2015-08-12 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体cd133×cd3的构建及应用
|
|
MX393599B
(es)
|
2015-04-29 |
2025-03-19 |
Radius Pharmaceuticals Inc |
Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
|
|
ES2755031T3
(es)
|
2015-05-18 |
2020-04-21 |
Lilly Co Eli |
Compuestos de anticuerpos biespecíficos ANTI-DKK-1-ANTI-RANKL
|
|
EP3299382B1
(en)
*
|
2015-05-20 |
2023-04-26 |
Osaka University |
Oligopeptide having proinflammatory cytokine secretion-inhibiting activity
|
|
EP3400003B1
(en)
*
|
2016-01-05 |
2023-05-03 |
The Trustees of Columbia University in the City of New York |
Compositions for regulating activity of inhibitor of dna binding-2 (id2) protein
|
|
WO2017123642A1
(en)
*
|
2016-01-12 |
2017-07-20 |
The Trustees Of The University Of Pennsylvania |
Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
|
|
EP3411066A1
(en)
|
2016-02-01 |
2018-12-12 |
Eli Lilly and Company |
Parathyroid hormone anti-rankl antibody fusion compounds
|
|
WO2017156058A1
(en)
|
2016-03-08 |
2017-09-14 |
Janssen Biotech, Inc. |
Gitr antibodies, methods, and uses
|
|
PT3458610T
(pt)
|
2016-05-25 |
2021-06-29 |
Inbiomotion Sl |
Tratamento terapêutico de cancro da mama baseado no estado de c-maf
|
|
AU2017294772B2
(en)
|
2016-07-14 |
2024-05-02 |
Scholar Rock, Inc. |
TGFB antibodies, methods, and uses
|
|
CN109890845B
(zh)
|
2016-10-28 |
2022-07-01 |
伊莱利利公司 |
抗rankl抗体及其用途
|
|
DK3565542T3
(da)
|
2017-01-05 |
2024-07-01 |
Radius Pharmaceuticals Inc |
Polymorphic forms of rad1901-2hcl
|
|
JP7672196B2
(ja)
|
2017-03-14 |
2025-05-07 |
アムジエン・インコーポレーテツド |
細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
|
|
WO2019102380A1
(en)
|
2017-11-22 |
2019-05-31 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-maf
|
|
KR20200135781A
(ko)
|
2018-03-26 |
2020-12-03 |
암젠 인크 |
세포 배양에서 생산된 항체의 총 비푸코실화 당형태
|
|
KR102792490B1
(ko)
|
2018-07-04 |
2025-04-04 |
래디어스 파마슈티컬스, 인코포레이티드 |
Rad1901-2hcl의 다형 형태
|
|
US11499928B2
(en)
*
|
2018-08-24 |
2022-11-15 |
University Of Wyoming |
Methods and systems for isochoric measurements using differential scanning calorimetry
|
|
WO2020070288A1
(en)
|
2018-10-05 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
EP3883610A4
(en)
|
2018-11-20 |
2022-11-02 |
Cornell University |
MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
|
|
MX2021009569A
(es)
|
2019-02-12 |
2021-09-08 |
Radius Pharmaceuticals Inc |
Procesos y compuestos.
|
|
MX2022003461A
(es)
|
2019-09-26 |
2022-04-19 |
Amgen Inc |
Metodos de produccion de composiciones de anticuerpos.
|
|
EP4110371A1
(en)
|
2020-01-24 |
2023-01-04 |
Radius Health, Inc. |
Methods of stimulating bone growth with abalopartide and denosumab
|
|
CN111793135A
(zh)
*
|
2020-05-11 |
2020-10-20 |
廊坊天光生物技术有限公司 |
一种用于检测血清中rankl含量的抗体对及其用途
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
MX2023004364A
(es)
|
2020-10-15 |
2023-05-03 |
Amgen Inc |
Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
|
|
AU2022289365A1
(en)
|
2021-06-07 |
2023-12-14 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
AU2022361382A1
(en)
|
2021-10-05 |
2024-03-28 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
WO2023179791A1
(en)
*
|
2022-03-24 |
2023-09-28 |
Angitia Biomedicines Limited |
Treatment of musculoskeletal disorders
|
|
EP4507779A1
(en)
|
2022-04-14 |
2025-02-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
AU2024256160A1
(en)
|
2023-04-20 |
2025-10-02 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|